Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04858269 · ClinicalTrials.gov registry record · Phase 2
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
A Phase 2 study of Oral Cavity Squamous Cell Carcinoma and Oropharynx Squamous Cell Carcinoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04858269 is a Phase 2 study of Oral Cavity Squamous Cell Carcinoma and Oropharynx Squamous Cell Carcinoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 32 participants, below the 135-participant average among 8 other Oral Cavity Squamous Cell Carcinoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04858269, a Phase 2 study of Oral Cavity Squamous Cell Carcinoma and Oropharynx Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
Study Locations (1)
North Carolina
- Wake Forest Baptist Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04858269
The ClinicalTrials.gov registry entry for NCT04858269 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 8 other Oral Cavity Squamous Cell Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Oral Cavity Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04858269 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04858269 about?
NCT04858269 is a clinical study titled "First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients". The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil
What is the current status of trial NCT04858269?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2021-05-27. Estimated completion is 2028-08.
What conditions does trial NCT04858269 study?
This clinical trial studies the following conditions: Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04858269?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04858269?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04858269 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Cavity Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RECRUITING · Phase 2
-
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
RECRUITING · Phase 2
-
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RECRUITING · Phase 2
-
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
RECRUITING · Phase 2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RECRUITING · Phase 2
-
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Oral Cavity Squamous Cell Carcinoma
All registered trials for this condition
Oropharynx Squamous Cell Carcinoma
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.